A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium Antagonist Reinfarction Italian Study (CRIS)

Franco Rengo, Pierugo Carbonin, Marco Pahor, Lorenzo De Caprio, Roberto Bernabei, Nicola Ferrara, Luciana Carosella, Domenico Acanfora, Stefania Parlati, Dino Vitale

Research output: Contribution to journalArticle

Abstract

A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalThe American Journal of Cardiology
Volume77
Issue number5
DOIs
Publication statusPublished - Feb 15 1996

Fingerprint

Verapamil
Myocardial Infarction
Calcium
Mortality
Placebos
Randomized Controlled Trials
Heart Failure
Confidence Intervals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A controlled trial of verapamil in patients after acute myocardial infarction : Results of the Calcium Antagonist Reinfarction Italian Study (CRIS). / Rengo, Franco; Carbonin, Pierugo; Pahor, Marco; De Caprio, Lorenzo; Bernabei, Roberto; Ferrara, Nicola; Carosella, Luciana; Acanfora, Domenico; Parlati, Stefania; Vitale, Dino.

In: The American Journal of Cardiology, Vol. 77, No. 5, 15.02.1996, p. 365-369.

Research output: Contribution to journalArticle

Rengo, F, Carbonin, P, Pahor, M, De Caprio, L, Bernabei, R, Ferrara, N, Carosella, L, Acanfora, D, Parlati, S & Vitale, D 1996, 'A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium Antagonist Reinfarction Italian Study (CRIS)', The American Journal of Cardiology, vol. 77, no. 5, pp. 365-369. https://doi.org/10.1016/S0002-9149(97)89365-4
Rengo, Franco ; Carbonin, Pierugo ; Pahor, Marco ; De Caprio, Lorenzo ; Bernabei, Roberto ; Ferrara, Nicola ; Carosella, Luciana ; Acanfora, Domenico ; Parlati, Stefania ; Vitale, Dino. / A controlled trial of verapamil in patients after acute myocardial infarction : Results of the Calcium Antagonist Reinfarction Italian Study (CRIS). In: The American Journal of Cardiology. 1996 ; Vol. 77, No. 5. pp. 365-369.
@article{527e3b4192954823a801d8164b1da705,
title = "A controlled trial of verapamil in patients after acute myocardial infarction: Results of the Calcium Antagonist Reinfarction Italian Study (CRIS)",
abstract = "A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91{\%} were men. During a mean follow-up of 23.5 months, 5.5{\%} of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95{\%} confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.",
author = "Franco Rengo and Pierugo Carbonin and Marco Pahor and {De Caprio}, Lorenzo and Roberto Bernabei and Nicola Ferrara and Luciana Carosella and Domenico Acanfora and Stefania Parlati and Dino Vitale",
year = "1996",
month = "2",
day = "15",
doi = "10.1016/S0002-9149(97)89365-4",
language = "English",
volume = "77",
pages = "365--369",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - A controlled trial of verapamil in patients after acute myocardial infarction

T2 - Results of the Calcium Antagonist Reinfarction Italian Study (CRIS)

AU - Rengo, Franco

AU - Carbonin, Pierugo

AU - Pahor, Marco

AU - De Caprio, Lorenzo

AU - Bernabei, Roberto

AU - Ferrara, Nicola

AU - Carosella, Luciana

AU - Acanfora, Domenico

AU - Parlati, Stefania

AU - Vitale, Dino

PY - 1996/2/15

Y1 - 1996/2/15

N2 - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.

AB - A multicenter, double-blind, randomized, placebo-controlled trial was conducted to assess the effects of verapamil on total mortality, cardiac mortality, reinfarction, and angina after an acute myocardial infarction. All patients, aged 30 to 75 years, consecutively admitted for acute myocardial infarction between 1985 and 1987 to the participating centers, and without contraindications to verapamil or history of severe heart failure were enrolled. Seven to 21 days (mean 13.8) after myocardial infarction, 531 patients were randomized to verapamil retard 360 mg/day, and 542 patients to placebo. At baseline, the 2 groups of patients had similar characteristics. Mean age was 55.5 years and 91% were men. During a mean follow-up of 23.5 months, 5.5% of the patients died. No differences between verapamil and placebo were observed in total mortality (n = 30 and 29, respectively) and cardiac death (n = 21 and 22, respectively). The verapamil group had nonsignificant lower reinfarction rates (n = 39 vs 49). The number of patients developing angina was significantly less in the verapamil group (n = 100 vs 132, RR = 0.8, 95% confidence interval 0.5 to 0.9). There were no differences in discontinuation of therapy caused by adverse reactions. This trial showed no effect of verapamil on mortality. The lower reinfarction rates found in the verapamil group are in agreement with the results of other studies.

UR - http://www.scopus.com/inward/record.url?scp=9044225950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044225950&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)89365-4

DO - 10.1016/S0002-9149(97)89365-4

M3 - Article

C2 - 8602564

AN - SCOPUS:9044225950

VL - 77

SP - 365

EP - 369

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -